 ironwood pharmaceuticals inc nasdaqirwd stake reduced by janus capital management llc  markets daily daily ratings  news for ironwood pharmaceuticals inc complete the form below to receive the latest headlines and analysts recommendationsfor ironwood pharmaceuticals inc with our free daily email newsletter follow themarketsdaily the markets daily recent posts hightower advisors llc has  position in sorrento therapeutics inc nasdaqsrne credit suisse ag has  million stake in anixter international inc axe advisory services network llc invests  million in j p morgan chase  co jpm big lots inc nysebig shares sold by credit suisse ag bhp billiton limited nysebhp downgraded by bidaskclub to “buy” tudor investment corp et al invests  in extra space storage inc exr the medicines company mdco shares sold by credit suisse ag seritage growth properties nysesrg shares bought by credit suisse ag nq mobile inc nq rating increased to hold at bidaskclub alimera sciences inc alim given a  price target by cowen and company analysts arlington asset investment corp ai reaches new week low after earnings miss blackrock enhanced global dividend trust nyseboe sets new year high at  aaron’s inc aan reaches new month high at  flushing financial corporation nasdaqffic stake decreased by ubs group ag tradition capital management llc sells  shares of goldman sachs group inc the nysegs tudor investment corp et al has  stake in epam systems inc epam dick’s sporting goods inc nysedks downgraded by zacks investment research first financial bancorp ffbc stake maintained by metropolitan life insurance co ny ringcentral inc nyserng stake held by metropolitan life insurance co ny dimensional fund advisors lp has  million stake in broadridge financial solutions inc nysebr ironwood pharmaceuticals inc nasdaqirwd stake reduced by janus capital management llc posted by mitch edgeman on jul th   no comments janus capital management llc decreased its stake in ironwood pharmaceuticals inc nasdaqirwd by  during the first quarter according to its most recent filing with the sec the institutional investor owned  shares of the biotechnology company’s stock after selling  shares during the period janus capital management llc owned  of ironwood pharmaceuticals worth  at the end of the most recent quarter several other institutional investors have also recently bought and sold shares of the company strs ohio boosted its position in ironwood pharmaceuticals by  in the first quarter strs ohio now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter pacad investment ltd purchased a new position in ironwood pharmaceuticals during the fourth quarter valued at approximately  raymond james financial services advisors inc purchased a new position in ironwood pharmaceuticals during the fourth quarter valued at approximately  jane street group llc purchased a new position in ironwood pharmaceuticals during the first quarter valued at approximately  finally karp capital management corp purchased a new position in ironwood pharmaceuticals during the first quarter valued at approximately   of the stock is currently owned by hedge funds and other institutional investors get ironwood pharmaceuticals inc alerts shares of ironwood pharmaceuticals inc irwd opened at  on wednesday the firm’s day moving average is  and its day moving average is  ironwood pharmaceuticals inc has a one year low of  and a one year high of  the company’s market cap is  billion ironwood pharmaceuticals nasdaqirwd last issued its quarterly earnings data on monday may th the biotechnology company reported  eps for the quarter missing analysts’ consensus estimates of  by  ironwood pharmaceuticals had a negative return on equity of  and a negative net margin of  the business had revenue of  million during the quarter compared to analysts’ expectations of  million during the same period in the previous year the business earned  earnings per share the business’s quarterly revenue was down  on a yearoveryear basis on average equities analysts anticipate that ironwood pharmaceuticals inc will post  eps for the current year illegal activity notice “ironwood pharmaceuticals inc nasdaqirwd stake reduced by janus capital management llc” was published by markets daily and is the sole property of of markets daily if you are viewing this article on another publication it was illegally copied and reposted in violation of us and international trademark and copyright law the legal version of this article can be viewed at httpswwwthemarketsdailycomironwoodpharmaceuticalsincirwdpositiondecreasedbyjanuscapitalmanagementllcupdatedupdatedupdatedhtml several research firms have commented on irwd mizuho lifted their target price on shares of ironwood pharmaceuticals from  to  and gave the stock a “buy” rating in a research report on friday april th wedbush reissued a “neutral” rating and set a  target price on shares of ironwood pharmaceuticals in a research report on tuesday may th bidaskclub cut shares of ironwood pharmaceuticals from a “buy” rating to a “hold” rating in a report on friday june th zacks investment research raised shares of ironwood pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on monday finally wells fargo  company initiated coverage on shares of ironwood pharmaceuticals in a report on wednesday may rd they issued an “outperform” rating and a  price target on the stock six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company the stock has an average rating of “buy” and an average target price of  in related news insider thomas a mccourt sold  shares of the business’s stock in a transaction that occurred on monday may th the shares were sold at an average price of  for a total transaction of  following the completion of the transaction the insider now owns  shares in the company valued at approximately  the transaction was disclosed in a document filed with the sec which is available at this hyperlink also insider halley e gilbert sold  shares of the business’s stock in a transaction that occurred on thursday june nd the stock was sold at an average price of  for a total transaction of  following the transaction the insider now owns  shares of the company’s stock valued at approximately  the disclosure for this sale can be found here  of the stock is owned by insiders ironwood pharmaceuticals company profile ironwood pharmaceuticals inc is a biotechnology company the company is advancing product opportunities in areas of unmet need including irritable bowel syndrome with constipation ibs c and chronic idiopathic constipation cic hyperuricemia associated with uncontrolled gout uncontrolled gastroesophageal reflux disease uncontrolled gerd and vascular and fibrotic diseases receive news  ratings for ironwood pharmaceuticals inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for ironwood pharmaceuticals inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ironwood pharmaceuticals inc irwd stock rating reaffirmed by jp morgan chase  co jul ironwood pharmaceuticals inc irwd stock rating reaffirmed by jp morgan chase  coellis wolfe amp capital investors ltd increased lululemon athletica inc lulu stake by  reported in q sec filing  shares of the company were exchanged for the quarter shares have been noted at  metlife inc now has b valuation the stock declined  or  reaching  on the news about  shares traded ironwood pharmaceuticals inc irwd has made its way to a month gain of  it has underperformed by  the spin healthcare sector shares of ironwood pharmaceuticals incon april  the stock rating was upgraded to outperform from market perform by cowen  company the firm is advancing product opportunities in areas of unmet need including irritable bowel syndrome with constipation and chronic idiopathic constipation cic hyperuricemia associated with uncontrolled gout uncontrolled gastroesophageal reflux disease uncontrolled gerd and vascular and fibrotic diseasesshares of ironwood pharmaceuticals closed the previous trading session at    with  shares trading hands it operates in human therapeutics business segmentsince february   it had  insider buys and  sales for  million activity ridgeworth cap ltd company invested  in ironwood pharmaceuticals inc nasdaqirwd royal fincl bank of canada stated it has  shares or  of all its holdings moreover swiss national bank  trust has  invested in ironwood pharmaceuticals inc following the completion of the transaction the insider now directly owns  shares of the companys stock valued at revenue per share is  the stock has overweight rating by barclays capital on monday january  navy seals may soon welcome first female member another woman has set her sights on becoming a special warfare combatant crewman thats a threeweek block of instruction mark walton spokesman for the naval special warfare command told the twoway when asked what makes training so hard  ironwood pharmaceuticals nasdaqirwd last posted its quarterly earnings results on monday may th emergent biosolutions inc has  buy ratings  holds and  sells even after the stock tumbled  from its high of  to a  billion market value through last closecovering sellside analysts have recently weighed in on shares of ironwood pharmaceuticals inc sold all  reduced  increased  new position  the funds in our partners database now hold  million shares up from  million shares in q the correct version of this news story can be read at httpstranscriptdailycomironwoodpharmaceuticalsincirwdsharesboughtbypointassetmanagementlpupdatedupdatedupdatedhtml nasdaqirwd  are held by point asset management limited partnership pitcairn has  invested in metlife inc nysemet for  shares nasdaqirwd credit suisse ag has  invested in ironwood pharmaceuticals inc  are held by cap impact advsr ltd millennium mgmt limited liability com accumulated  shares zacks owns  sharesbrokerage houses on average are recommending investors to hold webcom group inc ecor capital llc boosted its position in ironwood pharmaceuticals by  in the first quarter increasing profits are the best indication that a company can pay dividends and that the share price will trend upward parametrica management ltd purchased a new position in shares of ironwood pharmaceuticals during the first quarter valued at about  the consensus target price is  with  firms rating the stock a strong buy  firms rating the stock a buy six brokerages rating the company a hold one brokerage rating the company a underperform and lastly zero brokerages rating the company a sell therefore  are positive valuengine raised ironwood pharmaceuticals from a sell rating to a hold rating in a research report on friday june nd nasdaqirwd earnings growing rapidly the company was maintained on tuesday june  by mizuho the company was maintained on thursday july  by mizuho the firm has neutral rating given on friday february  by wedbush j p morgan chase  co reaffirmed a neutral rating and issued a  price target on shares of ironwood pharmaceuticals in a report on friday on friday july  the stock rating was maintained by mizuho with buy nasdaqirwd rating on monday october  nasdaqirwd shares shares for  were sold by graney thomas on wednesday february  ironwood pharmaceuticals presently has a consensus rating of buy and an average target price of the target price for ironwood pharmaceuti nasdaqirwd is share according to the consensus analysis of analysts working on the stock they expect  earnings per share down   or  from last years  per share bankshares of montreal can has invested  in ironwood pharmaceuticals incinvestors sentiment increased to  in q  its down  from  in q  funds opened positions while  raised stakes zurcher kantonalbank zurich cantonalbank reported  shares reliance trust of delaware invested  of its portfolio in metlife inc nysemet related news is it smart for kyrie irving to want out of cleveland life crippled in kashmir due to strike against killings restrictions alabama grandmother arrested accused of selling granddaughter for sex trumps son associates to face senate questions salman khans dabangg  finally gets a director  its not prabhudheva mercedes amg glc launched in india filipino president says will never visit lousy america polaris industries inc nysepii releases fy earnings guidance samsungs galaxy note  might come with a bixbyfriendly earset mi man gets weekends in jail for trying to sway jury ryan seacrest to return as host of american idol sean spicers interview with sean hannity time  channel charlie sheens  movie trailer blasted as offensive extremely tasteless share this hot news political analyst paul lisnek explains presidential pardon and what it means regarding impeachment jul     president trumps legal team is said to be looking for conflicts of interest among special counsel robert muellers investigators two sources tell the associated press the lawyers are researching the political affiliations and past history of muellers staff this was definitely the round that got me back into the championship jul     we are expecting to be in excess of  which will make it the number four all time for the open championship  thats because kuchar survived a gusty day at royal birkdale with a overpar  to finish the day at  under new portrait of prince george released to celebrate fourth birthday jul     princess charlotte was born in  wills and kates second child after prince george  the selective establishment states that its most important rule is to be kind trump désavoue son ministre de la justice — enquête russe jul     jeff sessions vers la sortie dianne feinstein siège à la commission judiciaire du sénat qui enquête également sur laffaire pour donald trump  le ministre de la justice jeff sessions naurait pas dû se récuser dans laffaire russe  syfy krypton superman prequel comiccon teaser trailer jul     the people and companies behindthescenes of krypton  krypton is being executive produced by david s obviously there is never a shortage of trouble for the family which always searches for justice analyst activity  guggenheim reiterates buy on apple nasdaqaapl jul     the insider gore albert jr sold  shares worth  million  shares were sold by riccio daniel j  worth m macnealy hoover investment mgmt has  shares nasdaqaapl for  shares  are held by ami asset mgmt marvel confirms daredevil season  and iron fist season  jul     from there we get the logos from each show then we get the teasers money shot the punisher  marvel broke out the biggest superhero of all for netflixs latest  the defenders  tease yellow maradol papayas linked to salmonella outbreak in us jul     eleven of  people  said they ate papayas which is a significantly higher proportion than typical papaya consumption but some people may have diarrhea so severe or develop sepsis a blood infection and need to be hospitalized newspaper india set aussies tough target after kaur hits  jul     the format of the world cup  roundrobin league among  teams followed by knockouts  must have made it tough on most teams  coming to indias bowling department the hopes will be pinned on the veteran jhulan goswami and her partner shikha pandey las vegas party the ideal open warmup for koepka jul     open in  is brilliant with a wedge and a putter i lined up way left with the wind whipping off the left said spieth  unlike some american players who grow used to the manicured layouts on which the majority of us susan rice meets with senate intel committee as part of russian federation probe jul     pelton said russias attempted meddling in the election violated one of the core foundations of american democracy for her part rice has strenuously denied any wrongdoing global ipl beauty machine market outlook  growth demand strategy forecast  jul     the report includes following key players in the professional d camera industry from different parts of the united states it also covers rotary pressure filters market opportunities and threats faced by the vendors in the united states regions  us moves to drop charges against extraders in london whale case jul     the us attorneys office said it no longer believes that it can rely on the testimony of iksil a police officer stands guard outside of the new york city headquarters of jpmorgan chase in may kentucky taxpayers to pay clerks legal fees jul     he said he would appeal that aspect of the judges ruling without prevailing party status there can be no attorneys fees davis declined to issue marriage licenses in the wake of the  supreme court decision legalizing samesex marriage what saif ali khan karan johar at loggerheads post iifa  jul     he wrote it was not supposed to be a big deal but i realised at some point that it might have offended kangana ranaut  in a letter published by a leading daily saif justified his stand and explained how a joke became the talk of the town ironwood pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report ironwood pharmaceuticals inc  product pipeline review   published by global markets direct product code  published may   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license ironwood pharmaceuticals inc  product pipeline review   published may   content info  pages description summary global markets directs ironwood pharmaceuticals inc  product pipeline review   provides an overview of the ironwood pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ironwood pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of ironwood pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ironwood pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the ironwood pharmaceuticals incs pipeline products reasons to buy evaluate ironwood pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of ironwood pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ironwood pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ironwood pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ironwood pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ironwood pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures ironwood pharmaceuticals inc snapshot ironwood pharmaceuticals inc overview key information key facts ironwood pharmaceuticals inc  research and development overview key therapeutic areas ironwood pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities ironwood pharmaceuticals inc  pipeline products glance ironwood pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities ironwood pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities ironwood pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities ironwood pharmaceuticals inc  drug profiles linaclotide product description mechanism of action rd progress iw product description mechanism of action rd progress iw product description mechanism of action rd progress iw product description mechanism of action rd progress iw product description mechanism of action rd progress ironwood pharmaceuticals inc  pipeline analysis ironwood pharmaceuticals inc  pipeline products by target ironwood pharmaceuticals inc  pipeline products by route of administration ironwood pharmaceuticals inc  pipeline products by molecule type ironwood pharmaceuticals inc  pipeline products by mechanism of action ironwood pharmaceuticals inc  recent pipeline updates ironwood pharmaceuticals inc  company statement ironwood pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables ironwood pharmaceuticals inc key information ironwood pharmaceuticals inc key facts ironwood pharmaceuticals inc  pipeline by indication  ironwood pharmaceuticals inc  pipeline by stage of development  ironwood pharmaceuticals inc  monotherapy products in pipeline  ironwood pharmaceuticals inc  partnered products in pipeline  ironwood pharmaceuticals inc  partnered products combination treatment modalities  ironwood pharmaceuticals inc  phase iii  ironwood pharmaceuticals inc  phase ii  ironwood pharmaceuticals inc  phase i  ironwood pharmaceuticals inc  preclinical  ironwood pharmaceuticals inc  pipeline by target  ironwood pharmaceuticals inc  pipeline by route of administration  ironwood pharmaceuticals inc  pipeline by molecule type  ironwood pharmaceuticals inc  pipeline products by mechanism of action  ironwood pharmaceuticals inc  recent pipeline updates  ironwood pharmaceuticals inc subsidiaries list of figures ironwood pharmaceuticals inc  pipeline by top  indication  ironwood pharmaceuticals inc  pipeline by stage of development  ironwood pharmaceuticals inc  monotherapy products in pipeline  ironwood pharmaceuticals inc  pipeline by top  target  ironwood pharmaceuticals inc  pipeline by top  route of administration  ironwood pharmaceuticals inc  pipeline by top  molecule type  ironwood pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved ironwood pharmaceuticals inc irwdo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile ironwood pharmaceuticals inc irwdo related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse irwdo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description ironwood pharmaceuticals inc incorporated on january   is a biotechnology company the company is advancing product opportunities in areas of unmet need including irritable bowel syndrome with constipation ibs c and chronic idiopathic constipation cic hyperuricemia associated with uncontrolled gout uncontrolled gastroesophageal reflux disease uncontrolled gerd and vascular and fibrotic diseases the company operates in human therapeutics business segment the companys product linaclotide is available to adult men and women suffering from ibs c or cic in the united states under the trademarked name linzess and is available to adult men and women suffering from ibs c in certain european countries under the trademarked name constella linaclotide is being developed and commercialized in other parts of the world by certain of its partners it is also advancing iw a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled gerdthe company manages its global supply and distribution of linaclotide and lesinurad through a combination of contract manufacturers and collaboration partners zurampic is approved for use in combination with a xanthine oxidase inhibitor xoi for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid sua levels with a xoi alone the company is engaged in the discovery and development of linaclotide to advance development programs including iw and iw targeting soluble guanylate cyclase sgc the company is advancing two linaclotide colonic release formulations linaclotide colonic release cr which is a second generation product candidate with the potential to improve abdominal pain relief in adult ibs c patients and linaclotide colonic release cr which is a product candidate with the potential to improve abdominal pain in patients with additional gastrointestinal gi disorders where lower abdominal pain is a predominant symptom such as nonconstipation subtypes of irritable bowel syndrome ibsthe company together with its partner is exploring development opportunities to enhance the clinical profile of linzess by studying linaclotide in additional indications and populations to assess its potential to treat various gi conditions it is also evaluating linaclotide as a potential treatment of the gi dysfunction associated with opioid induced constipation oic as of december   the company together with its partner had initiated two phase ii clinical pediatric studies in ibs c patients age  to  and functional constipation patients age  to  the company has initiated a phase iib clinical study of iw in patients with uncontrolled gerd the company is developing duzallo a fixeddose combination product of lesinurad and allopurinol an xoi which is included under the lesinurad license the food and drug administration fda accepted for review a new drug application nda for duzallo for the treatment of hyperuricemia in patients with uncontrolled goutthe companys sgc candidate iw is targeting diabetic complications resulting from vascular dysfunction and fibrosis such as resistant hypertension and diabetic nephropathy the company has initiated a phase iia openlabel placebocontrolled clinical study of iw  in patients with type  diabetes and hypertension the phase iia study is designed to evaluate the tolerability pharmacokinetic and pharmacodynamic effects of iw across multiple doses as well as to explore its effect on biomarkers the company has initiated a phase iia randomized double blind placebo controlled single dose clinical study of iw  designed to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of iw  in patients with type ii achalasiathe company competes with takeda pharmaceuticals limited synergy pharmaceuticals inc mylan nv takeda pharmaceuticals americas inc and sucampo ag » full overview of irwdo company address ironwood pharmaceuticals inc  binney stcambridge   ma    p f  company web links home page officers  directors name compensation terrance mcguire  peter hecht  thomas graney  mark currie  thomas mccourt  » more officers  directors ironwood pharmaceuticals inc news ironwood reflux drug appears effective safe in midstage trial jul   ironwood reflux drug appears effective safe in midstage trial jul   briefironwood pharmaceuticals reports q loss per share of  may   briefironwood pharmaceuticals qtrly loss per share  feb   briefironwood pharmaceuticals and allergan entered into amendment to license agreement dated april   feb   » more irwdo news related topics stocksstock screenerhealthcarebiotechnology  medical research ironwood pharmaceuticals inc irwd stock rating reaffirmed by jp morgan chase  co jul ironwood pharmaceuticals inc irwd stock rating reaffirmed by jp morgan chase  coellis wolfe amp capital investors ltd increased lululemon athletica inc lulu stake by  reported in q sec filing  shares of the company were exchanged for the quarter shares have been noted at  metlife inc now has b valuation the stock declined  or  reaching  on the news about  shares traded ironwood pharmaceuticals inc irwd has made its way to a month gain of  it has underperformed by  the spin healthcare sector shares of ironwood pharmaceuticals incon april  the stock rating was upgraded to outperform from market perform by cowen  company the firm is advancing product opportunities in areas of unmet need including irritable bowel syndrome with constipation and chronic idiopathic constipation cic hyperuricemia associated with uncontrolled gout uncontrolled gastroesophageal reflux disease uncontrolled gerd and vascular and fibrotic diseasesshares of ironwood pharmaceuticals closed the previous trading session at    with  shares trading hands it operates in human therapeutics business segmentsince february   it had  insider buys and  sales for  million activity ridgeworth cap ltd company invested  in ironwood pharmaceuticals inc nasdaqirwd royal fincl bank of canada stated it has  shares or  of all its holdings moreover swiss national bank  trust has  invested in ironwood pharmaceuticals inc following the completion of the transaction the insider now directly owns  shares of the companys stock valued at revenue per share is  the stock has overweight rating by barclays capital on monday january  navy seals may soon welcome first female member another woman has set her sights on becoming a special warfare combatant crewman thats a threeweek block of instruction mark walton spokesman for the naval special warfare command told the twoway when asked what makes training so hard  ironwood pharmaceuticals nasdaqirwd last posted its quarterly earnings results on monday may th emergent biosolutions inc has  buy ratings  holds and  sells even after the stock tumbled  from its high of  to a  billion market value through last closecovering sellside analysts have recently weighed in on shares of ironwood pharmaceuticals inc sold all  reduced  increased  new position  the funds in our partners database now hold  million shares up from  million shares in q the correct version of this news story can be read at httpstranscriptdailycomironwoodpharmaceuticalsincirwdsharesboughtbypointassetmanagementlpupdatedupdatedupdatedhtml nasdaqirwd  are held by point asset management limited partnership pitcairn has  invested in metlife inc nysemet for  shares nasdaqirwd credit suisse ag has  invested in ironwood pharmaceuticals inc  are held by cap impact advsr ltd millennium mgmt limited liability com accumulated  shares zacks owns  sharesbrokerage houses on average are recommending investors to hold webcom group inc ecor capital llc boosted its position in ironwood pharmaceuticals by  in the first quarter increasing profits are the best indication that a company can pay dividends and that the share price will trend upward parametrica management ltd purchased a new position in shares of ironwood pharmaceuticals during the first quarter valued at about  the consensus target price is  with  firms rating the stock a strong buy  firms rating the stock a buy six brokerages rating the company a hold one brokerage rating the company a underperform and lastly zero brokerages rating the company a sell therefore  are positive valuengine raised ironwood pharmaceuticals from a sell rating to a hold rating in a research report on friday june nd nasdaqirwd earnings growing rapidly the company was maintained on tuesday june  by mizuho the company was maintained on thursday july  by mizuho the firm has neutral rating given on friday february  by wedbush j p morgan chase  co reaffirmed a neutral rating and issued a  price target on shares of ironwood pharmaceuticals in a report on friday on friday july  the stock rating was maintained by mizuho with buy nasdaqirwd rating on monday october  nasdaqirwd shares shares for  were sold by graney thomas on wednesday february  ironwood pharmaceuticals presently has a consensus rating of buy and an average target price of the target price for ironwood pharmaceuti nasdaqirwd is share according to the consensus analysis of analysts working on the stock they expect  earnings per share down   or  from last years  per share bankshares of montreal can has invested  in ironwood pharmaceuticals incinvestors sentiment increased to  in q  its down  from  in q  funds opened positions while  raised stakes zurcher kantonalbank zurich cantonalbank reported  shares reliance trust of delaware invested  of its portfolio in metlife inc nysemet related news is it smart for kyrie irving to want out of cleveland life crippled in kashmir due to strike against killings restrictions alabama grandmother arrested accused of selling granddaughter for sex trumps son associates to face senate questions salman khans dabangg  finally gets a director  its not prabhudheva mercedes amg glc launched in india filipino president says will never visit lousy america polaris industries inc nysepii releases fy earnings guidance samsungs galaxy note  might come with a bixbyfriendly earset mi man gets weekends in jail for trying to sway jury ryan seacrest to return as host of american idol sean spicers interview with sean hannity time  channel charlie sheens  movie trailer blasted as offensive extremely tasteless share this hot news political analyst paul lisnek explains presidential pardon and what it means regarding impeachment jul     president trumps legal team is said to be looking for conflicts of interest among special counsel robert muellers investigators two sources tell the associated press the lawyers are researching the political affiliations and past history of muellers staff this was definitely the round that got me back into the championship jul     we are expecting to be in excess of  which will make it the number four all time for the open championship  thats because kuchar survived a gusty day at royal birkdale with a overpar  to finish the day at  under new portrait of prince george released to celebrate fourth birthday jul     princess charlotte was born in  wills and kates second child after prince george  the selective establishment states that its most important rule is to be kind trump désavoue son ministre de la justice — enquête russe jul     jeff sessions vers la sortie dianne feinstein siège à la commission judiciaire du sénat qui enquête également sur laffaire pour donald trump  le ministre de la justice jeff sessions naurait pas dû se récuser dans laffaire russe  syfy krypton superman prequel comiccon teaser trailer jul     the people and companies behindthescenes of krypton  krypton is being executive produced by david s obviously there is never a shortage of trouble for the family which always searches for justice analyst activity  guggenheim reiterates buy on apple nasdaqaapl jul     the insider gore albert jr sold  shares worth  million  shares were sold by riccio daniel j  worth m macnealy hoover investment mgmt has  shares nasdaqaapl for  shares  are held by ami asset mgmt marvel confirms daredevil season  and iron fist season  jul     from there we get the logos from each show then we get the teasers money shot the punisher  marvel broke out the biggest superhero of all for netflixs latest  the defenders  tease yellow maradol papayas linked to salmonella outbreak in us jul     eleven of  people  said they ate papayas which is a significantly higher proportion than typical papaya consumption but some people may have diarrhea so severe or develop sepsis a blood infection and need to be hospitalized newspaper india set aussies tough target after kaur hits  jul     the format of the world cup  roundrobin league among  teams followed by knockouts  must have made it tough on most teams  coming to indias bowling department the hopes will be pinned on the veteran jhulan goswami and her partner shikha pandey las vegas party the ideal open warmup for koepka jul     open in  is brilliant with a wedge and a putter i lined up way left with the wind whipping off the left said spieth  unlike some american players who grow used to the manicured layouts on which the majority of us susan rice meets with senate intel committee as part of russian federation probe jul     pelton said russias attempted meddling in the election violated one of the core foundations of american democracy for her part rice has strenuously denied any wrongdoing global ipl beauty machine market outlook  growth demand strategy forecast  jul     the report includes following key players in the professional d camera industry from different parts of the united states it also covers rotary pressure filters market opportunities and threats faced by the vendors in the united states regions  us moves to drop charges against extraders in london whale case jul     the us attorneys office said it no longer believes that it can rely on the testimony of iksil a police officer stands guard outside of the new york city headquarters of jpmorgan chase in may kentucky taxpayers to pay clerks legal fees jul     he said he would appeal that aspect of the judges ruling without prevailing party status there can be no attorneys fees davis declined to issue marriage licenses in the wake of the  supreme court decision legalizing samesex marriage what saif ali khan karan johar at loggerheads post iifa  jul     he wrote it was not supposed to be a big deal but i realised at some point that it might have offended kangana ranaut  in a letter published by a leading daily saif justified his stand and explained how a joke became the talk of the town ironwood pharmaceuticals inc  investor faqs overview business principles events corporate governance management team board of directors committees contact the board financial information sec filings annual reports quarterly results key ratios stock information historic stock lookup analyst coverage press releases investor contacts shareholder tools shareholder briefcase printed materials email alerts download library snapshot rss news feeds       share this on delicious digg facebook linkedin twitter what is this investor faqs show  hide all  on which exchange is ironwood listed and what is the ticker symbol ironwood is traded on the nasdaq stock market under the symbol irwd  when did ironwood go public ironwood went public on february    what is the cusip number for ironwoods class a common stock the cusip number for ironwoods class a common stock is x   where is ironwood incorporated ironwood is incorporated in the state of delaware  where is ironwoods headquarters ironwoods headquarters is located at  binney street cambridge ma  usa the main phone number is   how can i purchase shares shares can be purchased through a stockbroker of your choice ironwood does not have a direct stock purchase plan  do you pay dividends or is there a reinvestment plan currently ironwood does not offer a dividend or stock reinvestment plan  how can i replace my lost stock certificate you must contact our transfer agent computershare investor services computershare can look up your records and make any necessary adjustments there is a fee involved for replacing lost certificates computershares contact information is phone within the us   if calling from outside the us    web wwwcomputersharecom address for first class registered and certified mail computershare investor services po box  college station tx  usa address for overnight delivery computershare investor services  quality circle suite  college station tx   if my address changes whom should i notify you must send both your old and new addresses to our transfer agent computershare investor services by us mail each stockholder in question must sign the request for an address change phone within the us   if calling from outside the us    web wwwcomputersharecom address for first class registered and certified mail computershare investor services po box  college station tx  usa address for overnight delivery computershare investor services  quality circle suite  college station tx   how many employees does ironwood have as december   ironwood had approximately  employees  has ironwood ever had any stock splits ironwood has not completed any stock splits  when is ironwoods fiscal yearend december   who are ironwoods independent auditors ernst  young llp  who can i call if i have further questions ironwoods investor relations department is happy to answer any shareholder questions the number to contact investor relations is   do you have another question that hasnt been answered please submit your question using the form below fields marked with an  are required name    email    subject    comments    type in number      this helps ironwood pharmaceuticals inc prevent automated submissions   you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals  about us skip to main content you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website you are now leaving ironwoodpharmacom about us core values management team founders board of directors pharmaceutical advisory committee contact us transparency learn about ironwoods founding and our evolution into the commercial biotechnology company we are today about our name about our name ironwood has always taken the long view we hope to grow substantial value and one step at a time earn the right to build an enduring pharmaceutical company that helps people lead better lives so we named ourselves after the ironwood tree which can live for thousands of years in the harshest desert creating a shaded microclimate in which life thrives we also like that the word ironwood is both hard and soft iron like science is undeniable and strong wood like artistry and humanity is flexible adaptive and versatile the two words together represent our passion for the art and science of making medicines our community valuing ownership valuing ownership at ironwood being a shareholder is about more than holding our shares it’s about being an owner of our business that means we want you to understand the opportunities and risks we face and what drives our decisions ownership is a responsibility we take seriously because we are all owners too learn more about our ownerrelated business principles the art and science of making medicines connect with us about us ironwood is committed to the art and science of making medicines patient needs shape our business they inform our drugmaking process we rely on patients to help us understand and address those unmet needs whether we’re transforming knowledge into medicine or tackling the equally challenging task of delivering that medicine to people around the world patients inspire us shareholders shape our success being a shareholder of ironwood is about more than owning our shares its about being an owner of our business we hope to generate outstanding returns for our shareholders inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company employees shape our future at ironwood we’re building a team of talented individuals who embrace the incredibly challenging task of making medicines all our employees are equity holders which means we are careful stewards of our resources and we share the responsibility to build and grow this company our discovery and development processes have generated a product that’s approved in the united states the european union and a number of other countries as well as a robust pipeline we hope to continue earning the right to make medicines and one step at a time build an enduring pharmaceutical company that helps patients lead better lives follow ironwoodpharma tweets by ironwoodpharma ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview key programs approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ﻿ ironwood pharmaceuticals inc nasdaqirwd stake reduced by janus capital management llc  markets daily daily ratings  news for ironwood pharmaceuticals inc complete the form below to receive the latest headlines and analysts recommendationsfor ironwood pharmaceuticals inc with our free daily email newsletter follow themarketsdaily the markets daily recent posts hightower advisors llc has  position in sorrento therapeutics inc nasdaqsrne credit suisse ag has  million stake in anixter international inc axe advisory services network llc invests  million in j p morgan chase  co jpm big lots inc nysebig shares sold by credit suisse ag bhp billiton limited nysebhp downgraded by bidaskclub to “buy” tudor investment corp et al invests  in extra space storage inc exr the medicines company mdco shares sold by credit suisse ag seritage growth properties nysesrg shares bought by credit suisse ag nq mobile inc nq rating increased to hold at bidaskclub alimera sciences inc alim given a  price target by cowen and company analysts arlington asset investment corp ai reaches new week low after earnings miss blackrock enhanced global dividend trust nyseboe sets new year high at  aaron’s inc aan reaches new month high at  flushing financial corporation nasdaqffic stake decreased by ubs group ag tradition capital management llc sells  shares of goldman sachs group inc the nysegs tudor investment corp et al has  stake in epam systems inc epam dick’s sporting goods inc nysedks downgraded by zacks investment research first financial bancorp ffbc stake maintained by metropolitan life insurance co ny ringcentral inc nyserng stake held by metropolitan life insurance co ny dimensional fund advisors lp has  million stake in broadridge financial solutions inc nysebr ironwood pharmaceuticals inc nasdaqirwd stake reduced by janus capital management llc posted by mitch edgeman on jul th   no comments janus capital management llc decreased its stake in ironwood pharmaceuticals inc nasdaqirwd by  during the first quarter according to its most recent filing with the sec the institutional investor owned  shares of the biotechnology company’s stock after selling  shares during the period janus capital management llc owned  of ironwood pharmaceuticals worth  at the end of the most recent quarter several other institutional investors have also recently bought and sold shares of the company strs ohio boosted its position in ironwood pharmaceuticals by  in the first quarter strs ohio now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter pacad investment ltd purchased a new position in ironwood pharmaceuticals during the fourth quarter valued at approximately  raymond james financial services advisors inc purchased a new position in ironwood pharmaceuticals during the fourth quarter valued at approximately  jane street group llc purchased a new position in ironwood pharmaceuticals during the first quarter valued at approximately  finally karp capital management corp purchased a new position in ironwood pharmaceuticals during the first quarter valued at approximately   of the stock is currently owned by hedge funds and other institutional investors get ironwood pharmaceuticals inc alerts shares of ironwood pharmaceuticals inc irwd opened at  on wednesday the firm’s day moving average is  and its day moving average is  ironwood pharmaceuticals inc has a one year low of  and a one year high of  the company’s market cap is  billion ironwood pharmaceuticals nasdaqirwd last issued its quarterly earnings data on monday may th the biotechnology company reported  eps for the quarter missing analysts’ consensus estimates of  by  ironwood pharmaceuticals had a negative return on equity of  and a negative net margin of  the business had revenue of  million during the quarter compared to analysts’ expectations of  million during the same period in the previous year the business earned  earnings per share the business’s quarterly revenue was down  on a yearoveryear basis on average equities analysts anticipate that ironwood pharmaceuticals inc will post  eps for the current year illegal activity notice “ironwood pharmaceuticals inc nasdaqirwd stake reduced by janus capital management llc” was published by markets daily and is the sole property of of markets daily if you are viewing this article on another publication it was illegally copied and reposted in violation of us and international trademark and copyright law the legal version of this article can be viewed at httpswwwthemarketsdailycomironwoodpharmaceuticalsincirwdpositiondecreasedbyjanuscapitalmanagementllcupdatedupdatedupdatedhtml several research firms have commented on irwd mizuho lifted their target price on shares of ironwood pharmaceuticals from  to  and gave the stock a “buy” rating in a research report on friday april th wedbush reissued a “neutral” rating and set a  target price on shares of ironwood pharmaceuticals in a research report on tuesday may th bidaskclub cut shares of ironwood pharmaceuticals from a “buy” rating to a “hold” rating in a report on friday june th zacks investment research raised shares of ironwood pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on monday finally wells fargo  company initiated coverage on shares of ironwood pharmaceuticals in a report on wednesday may rd they issued an “outperform” rating and a  price target on the stock six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company the stock has an average rating of “buy” and an average target price of  in related news insider thomas a mccourt sold  shares of the business’s stock in a transaction that occurred on monday may th the shares were sold at an average price of  for a total transaction of  following the completion of the transaction the insider now owns  shares in the company valued at approximately  the transaction was disclosed in a document filed with the sec which is available at this hyperlink also insider halley e gilbert sold  shares of the business’s stock in a transaction that occurred on thursday june nd the stock was sold at an average price of  for a total transaction of  following the transaction the insider now owns  shares of the company’s stock valued at approximately  the disclosure for this sale can be found here  of the stock is owned by insiders ironwood pharmaceuticals company profile ironwood pharmaceuticals inc is a biotechnology company the company is advancing product opportunities in areas of unmet need including irritable bowel syndrome with constipation ibs c and chronic idiopathic constipation cic hyperuricemia associated with uncontrolled gout uncontrolled gastroesophageal reflux disease uncontrolled gerd and vascular and fibrotic diseases receive news  ratings for ironwood pharmaceuticals inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for ironwood pharmaceuticals inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ironwood pharmaceuticals  east cambridge  cambridge ma foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doironwood pharmaceuticalsofficeeast cambridge cambridgesavesharetipsphotos ironwood pharmaceuticalsno tips and reviewslog in to leave a tip herepostno tips yetwrite a short note about what you liked what to order or other helpful advice for visitors photorelated searchesironwood pharmaceuticals cambridge  ironwood pharmaceuticals cambridge photos  ironwood pharmaceuticals cambridge location  ironwood pharmaceuticals cambridge address  ironwood pharmaceuticals cambridge  ironwood pharmaceuticals cambridge  ironwood pharmaceuticals east cambridge cambridgeaboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano 語 한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in cambridgeabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfironwood pharmaceuticals binney stcambridge ma united statesget directions none listed see when people check inpeople tend to check in during these timestodaynonesunnonemon am– pmtue am– pm pm– pmwed am– pmthu–fri am– pmsee moreunited states » massachusetts » middlesex county » cambridge » east cambridgeprofessional  other places » officeis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     ironwood pharmaceuticals inc  investor relations overview business principles events corporate governance management team board of directors committees contact the board financial information sec filings annual reports quarterly results key ratios stock information historic stock lookup analyst coverage press releases investor contacts shareholder tools shareholder briefcase printed materials email alerts download library snapshot rss news feeds       share this on delicious digg facebook linkedin twitter what is this investor relations at ironwood were focused on delivering differentiated medicines to patients if we do this efficiently and effectively we hope to generate outstanding returns for our shareholders inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company these are not small goals but we believe they represent the best way to maximize longterm value for both patients and shareholders read more hide  mo    mo    yr nasdaq irwd     volume   change  quote delayed  minutes   being a shareholder of ironwood is about more than owning our shares its about being an owner of our business we want you to understand our decisions and actions and we will strive to effectively communicate the opportunities and risks involved in our business at each step along the way among ironwoods shareholders are our own employees and this ownership mentality influences our operations ironwoodians are careful stewards of the companys resources whether making a gonogo decision on a discovery program or booking travel to a conference every program is challenged to earn its way forward and every employee is challenged to earn the right to pursue the goal we all  employees and other shareholders alike  aspire to achieve making medicines that help people lead better lives   ir contacts meredith kaya senior director investor relations and corporate communications  mkayaironwoodpharmacom auditors ernst  young  clarendon street boston ma   transfer agent computershare investor services po box  college station tx   wwwcomputersharecom   featured reports  proxy statement apr   viewdownload pdf version »  k feb   viewdownload pdf version » latest q may   view filing »   events aug   at  pm et ironwood pharmaceuticals q  investor update conference call read more » view all events» you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals  wikipedia ironwood pharmaceuticals from wikipedia the free encyclopedia jump to navigation search ironwood pharmaceuticals inc type public traded as nasdaqirwd industry biofuels and bioproducts industry founded  headquarters cambridge massachusetts products bioproducts website wwwironwoodpharmacom ironwood pharmaceuticals inc is a drug manufacturer that develops and markets medicines of different types one of its main products linaclotide is drug approved by the us food and drug administration fda and marketed since december  in february  the company was approved allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the company is publicly listed on nasdaq with the symbol irwd contents  history  research and products  linaclotide  iw  bnc  iw  corporate affairs  patent notice  references  external links historyedit in  microbia inc changed its name to ironwood pharmaceuticals inc research and productsedit linaclotideedit this principal product of ironwood pharmaceuticals was approved by the us fda in august  and reached the us market in december  the drug is focused on treating irritable bowel syndrome and related symptoms which according to the national institutes of health nih affects around  of americans linaclotide is estimated to reach blockbuster status in around the year  based on the forecast of market research firm decision resources iwedit the company is also doing research on treatment for painful disorders of the small intestine and has an earlystage product called iw the drug has just passed phase a study in  and showed effects in treating functional dyspepsia fd bnc  iwedit bnc is an anxiolytic that ironwood licensed and performed rd on it was abandoned november  corporate affairsedit patent noticeedit in february  ironwood pharmaceuticals was issued allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the patented method aims at achieving stable condition of the drug at room temperature and can dissolve in stomach with capsule and suitable for oral dosing this is another step forward in research and experiments based on linaclotide usage referencesedit  httpsfinanceyahoocomnewsironwoodreceivesnoticeallowancemethodshtml  microbia announces name change to ironwood pharmaceuticals   httpdecisionresourcescomnewsandeventspressreleasesirritablebowelsyndrome  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolirwdo  httpclinicaltrialsgovshownct  httpwwwtraderscomironwoodpharmaceuticalsnewsironwoodpharmaceuticalsincironwoodreceivesnoticeofallowanceformethodsofuseformulatio external linksedit  retrieved from httpsenwikipediaorgwindexphptitleironwoodpharmaceuticalsoldid categories companies listed on nasdaqhidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ironwood pharmaceuticals  wikipedia ironwood pharmaceuticals from wikipedia the free encyclopedia jump to navigation search ironwood pharmaceuticals inc type public traded as nasdaqirwd industry biofuels and bioproducts industry founded  headquarters cambridge massachusetts products bioproducts website wwwironwoodpharmacom ironwood pharmaceuticals inc is a drug manufacturer that develops and markets medicines of different types one of its main products linaclotide is drug approved by the us food and drug administration fda and marketed since december  in february  the company was approved allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the company is publicly listed on nasdaq with the symbol irwd contents  history  research and products  linaclotide  iw  bnc  iw  corporate affairs  patent notice  references  external links historyedit in  microbia inc changed its name to ironwood pharmaceuticals inc research and productsedit linaclotideedit this principal product of ironwood pharmaceuticals was approved by the us fda in august  and reached the us market in december  the drug is focused on treating irritable bowel syndrome and related symptoms which according to the national institutes of health nih affects around  of americans linaclotide is estimated to reach blockbuster status in around the year  based on the forecast of market research firm decision resources iwedit the company is also doing research on treatment for painful disorders of the small intestine and has an earlystage product called iw the drug has just passed phase a study in  and showed effects in treating functional dyspepsia fd bnc  iwedit bnc is an anxiolytic that ironwood licensed and performed rd on it was abandoned november  corporate affairsedit patent noticeedit in february  ironwood pharmaceuticals was issued allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the patented method aims at achieving stable condition of the drug at room temperature and can dissolve in stomach with capsule and suitable for oral dosing this is another step forward in research and experiments based on linaclotide usage referencesedit  httpsfinanceyahoocomnewsironwoodreceivesnoticeallowancemethodshtml  microbia announces name change to ironwood pharmaceuticals   httpdecisionresourcescomnewsandeventspressreleasesirritablebowelsyndrome  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolirwdo  httpclinicaltrialsgovshownct  httpwwwtraderscomironwoodpharmaceuticalsnewsironwoodpharmaceuticalsincironwoodreceivesnoticeofallowanceformethodsofuseformulatio external linksedit  retrieved from httpsenwikipediaorgwindexphptitleironwoodpharmaceuticalsoldid categories companies listed on nasdaqhidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft ironwood pharmaceuticals inc  press releases overview business principles events corporate governance management team board of directors committees contact the board financial information sec filings annual reports quarterly results key ratios stock information historic stock lookup analyst coverage press releases investor contacts shareholder tools shareholder briefcase printed materials email alerts download library snapshot rss news feeds       share this on delicious digg facebook linkedin twitter what is this press releases year all years              all releases ironwood pharmaceuticals to host second quarter  investor update call jul    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced it will host its second quarter  investor update conference call and webcast at  pm eastern time on thursday august   individuals interested in participating in the call should dial   read more ironwood pharmaceuticals reports positive topline results from iw phase iib trial in uncontrolled gastroesophageal reflux disease jul    kb    iw  mg demonstrated a significant reduction in heartburn severity in patients with uncontrolled gerd   greater than  of patients treated with iw  mg achieved a clinically meaningful reduction in heartburn severity   iw  mg also showed reductions  read more ironwood pharmaceuticals to present at the goldman sachs th annual global healthcare conference jun    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the goldman sachs th annual global healthcare conference on thursday june   at  am pacific time  pm eastern time at the terranea resort in rancho palos verdes cal read more ironwood pharmaceuticals to present at the jefferies healthcare conference jun    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the jefferies healthcare conference on thursday june   at  pm eastern time at the grand hyatt in new york city the presentation will be followed by a question and answer sess read more ironwood pharmaceuticals to present at the bank of america merrill lynch healthcare conference may    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the bank of america merrill lynch healthcare conference on wednesday may   at  pm pacific time   pm eastern time in las vegas nevada a live  read more ironwood pharmaceuticals presents data further elucidating linaclotides effect on pain at digestive disease week®  may    kb    linaclotide delayed release improved abdominal pain independent of effects on bowel function in a phase iib study of patients with ibsc   results from linaclotide preclinical studies suggest potential for effects on visceral hypersensitivity in other conditions associated with visceral pain read more ironwood pharmaceuticals provides first quarter  investor update may    kb    linzess® linaclotide us net sales grew to  million in q  primarily driven by more than  growth in linzess volume yearoveryear   three linzess doses now available with the introduction of  mcg dose   multiple  pipeline catalysts expected read more ironwood pharmaceuticals to present new data for linaclotide linaclotide delayed release and iw at digestive disease week®  may    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd a commercial biotechnology company today announced that the company and its collaborators will present clinical and preclinical data for linaclotide and linaclotide delayed release as well as preclinical data for iw read more ironwood pharmaceuticals to host first quarter  investor update call apr    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced it will host its first quarter  investor update conference call and webcast at  am eastern time on monday may   individuals interested in participating in the call should dial   read more allergan and ironwood launch campaign designed to empower the nearly  million americans estimated to suffer from ibs and cic to talk about bowel health apr    kb   dublin and cambridge mass april   prnewswire  allergan plc nyseagn and ironwood pharmaceuticals inc nasdaqirwd in partnership with the american gastroenterological association aga initiated a campaign about the importance of bowel health in recognition of irritable bowel syndrome ibs awareness month at the vital signs of read more ironwood pharmaceuticals appoints dr christopher wright as senior vice president of global development and chief development officer apr    kb    dr wright enhances ironwoods medical and drug development expertise as the company advances an expanding mid to latestage pipeline  cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd a commercial biotechnology company today announced  read more ironwood pharmaceuticals to present at barclays global healthcare conference mar    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the barclays global healthcare conference on thursday march   at  am eastern time at the loews miami beach hotel a live webcast of ironwoods presentation w read more ironwood pharmaceuticals showcases progress delivering innovative medicines to patients and building a topperforming commercial biotech at rd day  mar    kb    commercial products expected to drive  compound annual growth rate cagr for ironwood revenue between  and  pipeline of innovative product candidates expected to accelerate highmargin revenue growth into late s and beyond   nearterm catalysts highlighted for key programs i read more ironwood pharmaceuticals to present at cowen and company th annual health care conference feb    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the cowen and company th annual health care conference on monday march   at  pm eastern time at the boston marriott copley place a live webcast of  read more ironwood pharmaceuticals to host rd day on march   feb    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will host a live webcast of its rd day on thursday march   beginning at  am eastern time members of the ironwood leadership team and external opinion leaders will provide rd and commercial insights into key  read more ironwood pharmaceuticals provides fourth quarter and full year  investor update feb    kb    ironwood revenue in  was  million an  increase over  driven primarily by  linzess® linaclotide us net sales of  million and expansion of linzess commercial margin to    key pipeline milestones in linaclotide colonic release vascularfibrotic disea read more ironwood pharmaceuticals to host fourth quarter and fullyear  investor update call feb    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced it will host its fourth quarter and fullyear  investor update conference call and webcast at  pm eastern time on tuesday february   individuals interested in participating in the call sho read more astellas and ironwood report positive topline results from phase iii linaclotide trial for patients with chronic constipation conducted in japan jan    kb   tokyo  cambridge massbusiness wire astellas pharma inc tse and ironwood pharmaceuticals inc nasdaqirwd announced today topline results indicating that the phase iii clinical trial of linaclotide conducted in japan in adults with chronic constipation cc met its primary endpoint  read more us food and drug administration approves  mcg dose of linzess® linaclotide for adults with chronic idiopathic constipation jan    kb   cambridge mass and dublin jan   prnewswire  ironwood pharmaceuticals inc nasdaq irwd and allergan plc nyse agn announced today that the us food and drug administration fda has approved a  mcg dose of linzess® linaclotide for the treatment of chronic idiopathic constipation cic in adult patients  read more ironwood pharmaceuticals demonstrates strong execution on strategy to build topperforming commercial biotech jan    kb    expect  compound annual growth rate cagr for ironwood revenue between  and    linzess® linaclotide  us net sales expected to be m with  commercial margin on track to exceed b by    continued rd innovation expected to deliver multipl read more showing  of  page         next   add release to briefcase you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one ironwood pharmaceuticals  news center skip to main content you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website newspress releases social media multimediaresourcesnews centerlatest press releasesironwood pharmaceuticals to host second quarter  investor update callironwood pharmaceuticals reports positive topline results from iw phase iib trial in uncontrolled gastroesophageal reflux diseaseironwood pharmaceuticals to present at the goldman sachs th annual global healthcare conferenceironwood pharmaceuticals to present at the jefferies healthcare conferencemedia contactmeredith kayamkayaironwoodpharmacomlatest tweets ironwood pharmaceuticals  binney street cambridge ma  tel  fax about usoverviewcore valuesmanagement teamfoundersboard of directors pharmaceutical advisory committeecontact ustransparencyour medicinesoverviewdiscovery of linaclotideglobal strategyrdoverviewapproachcollaborateoverviewaccessing additional productsglobalizationinvestorsoverviewbusiness principleseventscorp governancefinancial informationstock informationinvestor faqspress releasesinvestor contactsnewsoverviewpress releasessocial mediamultimediaresourcesjoin usoverviewcareer openingssales openingsour communityour expertise copyright   ironwood pharmaceuticals inc all rights reserved         privacy policy         terms of service         site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals  wikipedia ironwood pharmaceuticals from wikipedia the free encyclopedia jump to navigation search ironwood pharmaceuticals inc type public traded as nasdaqirwd industry biofuels and bioproducts industry founded  headquarters cambridge massachusetts products bioproducts website wwwironwoodpharmacom ironwood pharmaceuticals inc is a drug manufacturer that develops and markets medicines of different types one of its main products linaclotide is drug approved by the us food and drug administration fda and marketed since december  in february  the company was approved allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the company is publicly listed on nasdaq with the symbol irwd contents  history  research and products  linaclotide  iw  bnc  iw  corporate affairs  patent notice  references  external links historyedit in  microbia inc changed its name to ironwood pharmaceuticals inc research and productsedit linaclotideedit this principal product of ironwood pharmaceuticals was approved by the us fda in august  and reached the us market in december  the drug is focused on treating irritable bowel syndrome and related symptoms which according to the national institutes of health nih affects around  of americans linaclotide is estimated to reach blockbuster status in around the year  based on the forecast of market research firm decision resources iwedit the company is also doing research on treatment for painful disorders of the small intestine and has an earlystage product called iw the drug has just passed phase a study in  and showed effects in treating functional dyspepsia fd bnc  iwedit bnc is an anxiolytic that ironwood licensed and performed rd on it was abandoned november  corporate affairsedit patent noticeedit in february  ironwood pharmaceuticals was issued allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the patented method aims at achieving stable condition of the drug at room temperature and can dissolve in stomach with capsule and suitable for oral dosing this is another step forward in research and experiments based on linaclotide usage referencesedit  httpsfinanceyahoocomnewsironwoodreceivesnoticeallowancemethodshtml  microbia announces name change to ironwood pharmaceuticals   httpdecisionresourcescomnewsandeventspressreleasesirritablebowelsyndrome  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolirwdo  httpclinicaltrialsgovshownct  httpwwwtraderscomironwoodpharmaceuticalsnewsironwoodpharmaceuticalsincironwoodreceivesnoticeofallowanceformethodsofuseformulatio external linksedit  retrieved from httpsenwikipediaorgwindexphptitleironwoodpharmaceuticalsoldid categories companies listed on nasdaqhidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ironwood pharmaceuticals  our medicine skip to main content you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website you are now leaving ironwoodpharmacom our medicines discovery of linaclotide global strategy contact us our medicines   click here for full us prescribing information including boxed warning »learn more about linzess® » click here for full us prescribing information including limitations of use and boxed warning »learn more about zurampic® »   grant applications and other support » ironwood pharmaceuticals  binney street cambridge ma  tel  fax  nrzurus  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview key programs approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        linzess® is a registered trademark of ironwood pharmaceuticals inc        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals inc  investor relations overview business principles events corporate governance management team board of directors committees contact the board financial information sec filings annual reports quarterly results key ratios stock information historic stock lookup analyst coverage press releases investor contacts shareholder tools shareholder briefcase printed materials email alerts download library snapshot rss news feeds       share this on delicious digg facebook linkedin twitter what is this investor relations at ironwood were focused on delivering differentiated medicines to patients if we do this efficiently and effectively we hope to generate outstanding returns for our shareholders inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company these are not small goals but we believe they represent the best way to maximize longterm value for both patients and shareholders read more hide  mo    mo    yr nasdaq irwd     volume   change  quote delayed  minutes   being a shareholder of ironwood is about more than owning our shares its about being an owner of our business we want you to understand our decisions and actions and we will strive to effectively communicate the opportunities and risks involved in our business at each step along the way among ironwoods shareholders are our own employees and this ownership mentality influences our operations ironwoodians are careful stewards of the companys resources whether making a gonogo decision on a discovery program or booking travel to a conference every program is challenged to earn its way forward and every employee is challenged to earn the right to pursue the goal we all  employees and other shareholders alike  aspire to achieve making medicines that help people lead better lives   ir contacts meredith kaya senior director investor relations and corporate communications  mkayaironwoodpharmacom auditors ernst  young  clarendon street boston ma   transfer agent computershare investor services po box  college station tx   wwwcomputersharecom   featured reports  proxy statement apr   viewdownload pdf version »  k feb   viewdownload pdf version » latest q may   view filing »   events aug   at  pm et ironwood pharmaceuticals q  investor update conference call read more » view all events» you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals  our medicine skip to main content you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website you are now leaving ironwoodpharmacom our medicines discovery of linaclotide global strategy contact us our medicines   click here for full us prescribing information including boxed warning »learn more about linzess® » click here for full us prescribing information including limitations of use and boxed warning »learn more about zurampic® »   grant applications and other support » ironwood pharmaceuticals  binney street cambridge ma  tel  fax  nrzurus  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview key programs approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        linzess® is a registered trademark of ironwood pharmaceuticals inc        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals  contact us skip to main content you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website you are now leaving ironwoodpharmacom about us core values management team founders board of directors pharmaceutical advisory committee contact us transparency ironwood pharmaceuticals  binney street cambridge ma  entrance at the corner of rogers  fulkerson t  f  public transportation » driving directions » contact us general inquiries »patient inquiries regarding ironwoodsponsored clinical trials »media inquiries »investigator inquiries regarding ironwoodsponsored clinical trials »investor relations inquiries »investigator inquiries regarding investigatorinitiated studies »partnering inquiries »scientific inquiries regarding ironwood investigational medicines »health care professional inquiries regarding aggregate spend »grant applications and other support » for linzess® medical inquiries health care professionals and consumers if you are a consumer and have specific medical questions we advise you to consult with your health care professional if you have questions regarding linzess® linaclotide please contact the medical information and communication department of our partner allergan plc at   extension  operators are available monday through friday  am –  pm eastern time  am –  pm central time click here for full prescribing information including boxed warning » directions via public transportation ironwood is conveniently located on the cambridge ezride shuttle route and walking distance from both the kendall square red line and lechmere green line t stops from the kendall square red line t stopfrom the kendall square red line t stop walk through the marriott hotel lobby and exit on the broadway side cross immediately onto the opposite side of broadway at the pedestrian crosswalk follow broadway to the left until you reach a set of lights and a paved treelined footpath on your right this is not a street but a pedestrian footpath take a right onto the path and at the end of the path cross over binney street and take a left onto binney after crossing follow binney one block and take a right onto fulkerson street the entrance to  binney is on the right on the corner of fulkerson and rogers streets across from metropolitan pipe and supply from the lechmere green line t stopfrom the lechmere green line t stop make a right on cambridge street and walk two blocks to third street make a left on third street and walk approximately  blocks to binney street make a right on binney and walk  blocks to fulkerson street take a right onto fulkerson street the entrance to  binney is on the right on the corner of fulkerson and rogers streets across from metropolitan pipe and supply ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview key programs approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        linzess® is a registered trademark of ironwood pharmaceuticals inc        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry ironwood pharmaceuticals  wikipedia ironwood pharmaceuticals from wikipedia the free encyclopedia jump to navigation search ironwood pharmaceuticals inc type public traded as nasdaqirwd industry biofuels and bioproducts industry founded  headquarters cambridge massachusetts products bioproducts website wwwironwoodpharmacom ironwood pharmaceuticals inc is a drug manufacturer that develops and markets medicines of different types one of its main products linaclotide is drug approved by the us food and drug administration fda and marketed since december  in february  the company was approved allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the company is publicly listed on nasdaq with the symbol irwd contents  history  research and products  linaclotide  iw  bnc  iw  corporate affairs  patent notice  references  external links historyedit in  microbia inc changed its name to ironwood pharmaceuticals inc research and productsedit linaclotideedit this principal product of ironwood pharmaceuticals was approved by the us fda in august  and reached the us market in december  the drug is focused on treating irritable bowel syndrome and related symptoms which according to the national institutes of health nih affects around  of americans linaclotide is estimated to reach blockbuster status in around the year  based on the forecast of market research firm decision resources iwedit the company is also doing research on treatment for painful disorders of the small intestine and has an earlystage product called iw the drug has just passed phase a study in  and showed effects in treating functional dyspepsia fd bnc  iwedit bnc is an anxiolytic that ironwood licensed and performed rd on it was abandoned november  corporate affairsedit patent noticeedit in february  ironwood pharmaceuticals was issued allowance by the united states patent and trademark office uspto to apply a patent on linzess and will be protect through  the patented method aims at achieving stable condition of the drug at room temperature and can dissolve in stomach with capsule and suitable for oral dosing this is another step forward in research and experiments based on linaclotide usage referencesedit  httpsfinanceyahoocomnewsironwoodreceivesnoticeallowancemethodshtml  microbia announces name change to ironwood pharmaceuticals   httpdecisionresourcescomnewsandeventspressreleasesirritablebowelsyndrome  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolirwdo  httpclinicaltrialsgovshownct  httpwwwtraderscomironwoodpharmaceuticalsnewsironwoodpharmaceuticalsincironwoodreceivesnoticeofallowanceformethodsofuseformulatio external linksedit  retrieved from httpsenwikipediaorgwindexphptitleironwoodpharmaceuticalsoldid categories companies listed on nasdaqhidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ironwood pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports ironwood pharmaceuticals inc  product pipeline review  ironwood pharmaceuticals inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports ironwood pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘ironwood pharmaceuticals inc  product pipeline review  ’ provides an overview of the ironwood pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of ironwood pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of ironwood pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ironwood pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the ironwood pharmaceuticals inc’s pipeline productsreasons to buy evaluate ironwood pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of ironwood pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ironwood pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ironwood pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ironwood pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ironwood pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures ironwood pharmaceuticals inc snapshot ironwood pharmaceuticals inc overview key information key facts ironwood pharmaceuticals inc  research and development overview key therapeutic areas ironwood pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities ironwood pharmaceuticals inc  pipeline products glance ironwood pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities ironwood pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities ironwood pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities ironwood pharmaceuticals inc  drug profiles linaclotide product description mechanism of action rd progress iw product description mechanism of action rd progress iw product description mechanism of action rd progress iw product description mechanism of action rd progress iw product description mechanism of action rd progress ironwood pharmaceuticals inc  pipeline analysis ironwood pharmaceuticals inc  pipeline products by target ironwood pharmaceuticals inc  pipeline products by route of administration ironwood pharmaceuticals inc  pipeline products by molecule type ironwood pharmaceuticals inc  pipeline products by mechanism of action ironwood pharmaceuticals inc  recent pipeline updates ironwood pharmaceuticals inc  company statement ironwood pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesironwood pharmaceuticals inc key information ironwood pharmaceuticals inc key facts ironwood pharmaceuticals inc  pipeline by indication  ironwood pharmaceuticals inc  pipeline by stage of development  ironwood pharmaceuticals inc  monotherapy products in pipeline  ironwood pharmaceuticals inc  partnered products in pipeline  ironwood pharmaceuticals inc  partnered products combination treatment modalities  ironwood pharmaceuticals inc  phase iii  ironwood pharmaceuticals inc  phase ii  ironwood pharmaceuticals inc  phase i  ironwood pharmaceuticals inc  preclinical  ironwood pharmaceuticals inc  pipeline by target  ironwood pharmaceuticals inc  pipeline by route of administration  ironwood pharmaceuticals inc  pipeline by molecule type  ironwood pharmaceuticals inc  pipeline products by mechanism of action  ironwood pharmaceuticals inc  recent pipeline updates  ironwood pharmaceuticals inc subsidiaries list of figuresironwood pharmaceuticals inc  pipeline by top  indication  ironwood pharmaceuticals inc  pipeline by stage of development  ironwood pharmaceuticals inc  monotherapy products in pipeline  ironwood pharmaceuticals inc  pipeline by top  target  ironwood pharmaceuticals inc  pipeline by top  route of administration  ironwood pharmaceuticals inc  pipeline by top  molecule type  ironwood pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send ironwood pharmaceuticals inc irwd soars  on july   equitiescom breaking news previous next stocks end mixed as earnings continue in droves how to grow your new business ​mark dubowitz from the foundation for defense of democracies on us policy toward russia ​time for convertible securities ​working with  types of global influencers usglobal canada news log in login to your account log in remember me forgot your password forgot your username register news ironwood pharmaceuticals inc irwd soars  on july  equities staff follow  friday  july   est market summary  follow ironwood pharmaceuticals inc is a a pharmaceutical company last price   last trade jul   change   change percent   open   prev close   high   low    week high    week low   market cap  pe ratio  volume  exchange ngs irwd  market data  news irwd  stock valuation report trade ironwood pharmaceuticals inc irwd had a good day on the market for friday july  as shares jumped  to close at  about  million shares traded hands on  trades for the day compared with an average daily volume of  million shares out of a total float of  million after opening the trading day at  shares of ironwood pharmaceuticals inc stayed within a range of  to  with todays gains ironwood pharmaceuticals inc now has a market cap of  billion shares of ironwood pharmaceuticals inc have been trading within a range of  and  over the last year and it had a day sma of  and a day sma of  ironwood pharmaceuticals inc is a biotechnology company which is focused on advancing innovative product opportunities in areas of large unmet needs such as constipation gastrointestinal disorders hyperuricemia among others ironwood pharmaceuticals inc is based out of cambridge ma and has some  employees its ceo is  for a complete fundamental analysis of ironwood pharmaceuticals inc check out equitiescom’s stock valuation analysis report for irwd want to invest with the experts subscribe to equities premium newsletters today visit httpwwwequitiespremiumcom to learn more about guild investment’s market commentary and adam sarhan’s find leading stocks today ironwood pharmaceuticals inc is also a component of the russell  the russell  is one of the leading indices tracking smallcap companies in the united states its maintained by russell investments an industry leader in creating and maintaining indices and consists of the smallest  stocks from the broader russell  index russells indices differ from traditional indices like the dow jones industrial average djia or sp  whose members are selected by committee because they base membership entirely on an objective rules based methodology the  largest companies by market cap make up the russell  with the  smaller companies making up the russell  its a simple approach that gives a broad unbiased look at the smallcap market as a whole to get more information on ironwood pharmaceuticals inc and to follow the company’s latest updates you can visit the company’s profile page here irwd’s profile for more news on the financial markets and emerging growth companies be sure to visit equitiescom’s newsdesk also don’t forget to signup for our daily email newsletter to ensure you don’t miss out on any of our best stories all data provided by quotemedia and was accurate as of pm et disclosure the views and opinions expressed in this article are those of the authors and do not represent the views of equitiescom readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions to read our full disclosure please go to httpwwwequitiescomdisclaimer comments you have to be logged in to leave a comment take me to log in dont have an account × you must log in first im sorry but in order to complete what youre trying to do you must be logged in take me to log in dont have an account im good for now more on equitiescom could the missouri prescription drug monitoring programs use of privatesector data be a national prototype the last tycoon review – glamour glitter and nazism in hollywoods golden age vibrant health products issues allergy alert on undeclared egg in livegfree gluten free classic soft white hamburger buns trending articles ​pro the new digital currency solves the biggest problem bitcoin can’t ​mgx minerals xmgcnx transforming oil wastewater to power the tech future ​liberty one’s pocitos west project positions it perfectly for the lithium supercycle ​nxtid’s fit pay adding secure shine to new token smart rings how millennials are changing the housing market ​dynacert brings measurable efficiency to a global auto industry in need of reducing carbon emissions emerging growth writ media group inc writ media group inc produces films television programs and similar entertainment programs for various media formats private markets california green tree development california green tree development llc cgtd is a forprofit llc that plans on using california’s booming market of legal cannabis products for medical purposes as an unprecedented resource cannabis has… mesamarshall  well project mesa resources mesa is sponsoring the development of the two well direct drilling project  mesamarshall  mesa founded in  is engaged in the acquisition exploration and development of… corporate sitepremium productsadvertisingrss feeds aboutcontactsite maptestimonials privacy policyterms and conditionsdisclaimerconference   equities  all dates and time are being displayed in eastern standard time est × follow companies mentioned in this article  follow ironwood pharmaceuticals inc ﻿ ironwood pharmaceuticals inc  product pipeline review   customer loginsign up homeprbuzz featuresall press releasesautomotive press releasesbook press releasebusiness press releasecomputer press releaseseducation press releasesenergy  environment press releasesentertainment  arts press releasesfamily  parenting press releasesfashion press releasesgovernment  politics press releaseshealth  fitness press releasespersonal finance press releaseshome  garden press releaseslifestyle press releasesnon profit press releasessports press releasestechnology press releasestravel press releasescontact uscustomer feedbackfaq javascript is currently disabledplease enable it for a better experience of jumi ironwood pharmaceuticals inc  product pipeline review   ironwood pharmaceuticals inc  product pipeline review   summary this ‘ironwood pharmaceuticals inc  product pipeline review  ’ provides an overview of the ironwood pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ironwood pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects browse report with toc  httpwwwmarketresearchstorecomreportironwoodpharmaceuticalsincproductpipelinereview   global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from research proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by research team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope   the report provides brief overview of ironwood pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of ironwood pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the ironwood pharmaceuticals inc’s pipeline products request sample on this report  httpwwwmarketresearchstorecomreportironwoodpharmaceuticalsincproductpipelinereviewrequestsample reasons to buy  evaluate ironwood pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of ironwood pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the ironwood pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of ironwood pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of ironwood pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of ironwood pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues   this press release has been viewed  times on pr buzz customer testimonialsterms  conditionswriting helppartnersall releases javascript is currently disabledplease enable it for a better experience of jumi ironwood pharmaceuticals  join us skip to main content you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website you are now leaving ironwoodpharmacom join us career openings sales openings our community our expertise learn about ironwoods founding and our evolution into the commercial biotechnology company we are today read about our culture of innovation careers not jobs careers not jobs every employee at ironwood has the opportunity to have an impact and is expected to take full advantage of that opportunity we share a responsibility to build and grow this company and we have openmic meetings opendoor policies and an openaccess social intranet to encourage everyone to contribute we expect people to take initiative and we train everyone at every level to be a leader we know that working well together is the only way we’ll have a chance at overcoming the many hurdles along the path to making medicines and we seek out people who thrive in a collaborative environment once we find those people we support their aspirations we’ve had bench scientists move into a variety of positions including regulatory and facilities and we’ve helped finance experts transition to operations and formulation scientists move into manufacturing we’re passionate about our business and we encourage our colleagues to follow their passion across job descriptions or departments the art and science of making medicines our community how are we connected our core values careers at ironwood at ironwood we’re focused on three goals transforming knowledge into medicines that make a difference for patients creating value that will inspire the continued support of our fellow shareholders and building a team that passionately pursues excellence achieving these goals is incredibly difficult and we’re looking for people who are up to and inspired by the challenge  new opportunitiesassociate director analytical development »hq cambridge  dept cmc pharmaceutical developmentdirector sr director analytical operations »hq cambridge  dept commercialsr manager supply chain  trade operations »hq cambridge  dept supply chainmedical science liaison  midwest »remote  dept medical affairssr drug safety associate »hq cambridge  dept drug safetyview all career opportunities » follow ironwoodpharma tweets by ironwoodpharma ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview key programs approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license ironwood pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals ironwood pharmaceuticals inc  product pipeline review   published may  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample ironwood pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘ironwood pharmaceuticals inc  product pipeline review  ’ provides an overview of the ironwood pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ironwood pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of ironwood pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of ironwood pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the ironwood pharmaceuticals inc’s pipeline products reasons to buy  evaluate ironwood pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of ironwood pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the ironwood pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of ironwood pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of ironwood pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of ironwood pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  ironwood pharmaceuticals inc snapshot  ironwood pharmaceuticals inc overview  key information  key facts  ironwood pharmaceuticals inc  research and development overview  key therapeutic areas  ironwood pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  ironwood pharmaceuticals inc  pipeline products glance  ironwood pharmaceuticals inc  late stage pipeline products  phase iii productscombination treatment modalities  ironwood pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  ironwood pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  ironwood pharmaceuticals inc  drug profiles  linaclotide  product description  mechanism of action  rd progress  iw  product description  mechanism of action  rd progress  iw  product description  mechanism of action  rd progress  iw  product description  mechanism of action  rd progress  iw  product description  mechanism of action  rd progress  ironwood pharmaceuticals inc  pipeline analysis  ironwood pharmaceuticals inc  pipeline products by target  ironwood pharmaceuticals inc  pipeline products by route of administration  ironwood pharmaceuticals inc  pipeline products by molecule type  ironwood pharmaceuticals inc  pipeline products by mechanism of action  ironwood pharmaceuticals inc  recent pipeline updates  ironwood pharmaceuticals inc  company statement  ironwood pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables ironwood pharmaceuticals inc key information  ironwood pharmaceuticals inc key facts  ironwood pharmaceuticals inc  pipeline by indication   ironwood pharmaceuticals inc  pipeline by stage of development   ironwood pharmaceuticals inc  monotherapy products in pipeline   ironwood pharmaceuticals inc  partnered products in pipeline   ironwood pharmaceuticals inc  partnered products combination treatment modalities   ironwood pharmaceuticals inc  phase iii   ironwood pharmaceuticals inc  phase ii   ironwood pharmaceuticals inc  phase i   ironwood pharmaceuticals inc  preclinical   ironwood pharmaceuticals inc  pipeline by target   ironwood pharmaceuticals inc  pipeline by route of administration   ironwood pharmaceuticals inc  pipeline by molecule type   ironwood pharmaceuticals inc  pipeline products by mechanism of action   ironwood pharmaceuticals inc  recent pipeline updates   ironwood pharmaceuticals inc subsidiaries  list of figures ironwood pharmaceuticals inc  pipeline by top  indication   ironwood pharmaceuticals inc  pipeline by stage of development   ironwood pharmaceuticals inc  monotherapy products in pipeline   ironwood pharmaceuticals inc  pipeline by top  target   ironwood pharmaceuticals inc  pipeline by top  route of administration   ironwood pharmaceuticals inc  pipeline by top  molecule type   ironwood pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and europe bcg vaccine market  analysis and outlook to  jul  eu research  pages    code  mrs   this report presents a comprehensive overview of the bcg vaccine market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bcg vaccine industry this report focus global and europe market it covers details playe read more global onychomycosis tinea unguium drug detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in onychomycosis tinea unguium drug industry this report fo read more life science analytics  global market outlook  jun  stratistics mrc  pages    code  mrs   according to stratistics mrc the global life science analytics market is expected to grow from  billion in  to reach  billion by  with a cagr of  some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications increasing need of these solutions especially in clinical trials and improvements in technological advancements however lack of skilled professionals huge implementation costs and financial limitations read more chronic kidney disease ckd drugs  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global chronic kidney disease ckd drugs market is expected to grow from  billion in  to reach  billion by  with a cagr of  drivers that are shaping the global market include growing incidences of chronic kidney diseases rise in aged population rising incidence of diabetes and obesity related disorders significant unmet requirements and beneficial reimbursement policies on the other hand factors such as intense competition fr read more acaricides  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global acaricides market is expected to grow from  million in  to reach  million by  with a cagr of  high demand for meat dairy products and crops growth in crop protection industry and rise in productivity are some of the factors propelling the market growth however increase in cost alternative acaricides sources and regulatory restrictions are the factors suppressing the market on the other hand expansion of bioactive aca read more global and united states bacillus subtilis depth research report  jul  united states research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a depth research report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus united states market it covers details players regions product type and other details as following major companies bayer germany basf germany tonglu huifeng china kernel biotech china w read more global bacterial vaginosis drug market rport  jun  bisreport  pages    code  mrs   global bacterial vaginosis drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the bacterial vaginosis drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years bacterial vaginosis drug market size to maintain read more global alzheimers disease drug market rport  jun  bisreport  pages    code  mrs   global alzheimer’s disease drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the alzheimer’s disease drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years alzheimer’s disease drug market size to maintain read more global protein powder detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in protein powder industry this report splits protein powder market price size first speciality second speciality protein powder flavors which covers the history data information from  to  and forecast from  to  this report focus glob read more opioidinduced constipation oic  pipeline review h  jul  global markets direct  pages    code  mrs   opioidinduced constipation oic  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide opioidinduced constipation oic  pipeline review h  provides an overview of the opioidinduced constipation oic toxicology pipeline landscape opioids are effective pain relievers but often have the side effect of constipation these medicines affect the gastrointestinal tract in a variety of ways opioids increase the amo read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports ironwood pharmaceuticals inc  press releases overview business principles events corporate governance management team board of directors committees contact the board financial information sec filings annual reports quarterly results key ratios stock information historic stock lookup analyst coverage press releases investor contacts shareholder tools shareholder briefcase printed materials email alerts download library snapshot rss news feeds       share this on delicious digg facebook linkedin twitter what is this press releases year all years              all releases ironwood pharmaceuticals announces proposed public offering of common stock feb    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced that it has commenced a  million underwritten public offering of its class a common stock all of the shares are being offered by ironwood ironwood will grant the underwriters a day option to purchas read more ironwood receives notice of allowance for methods of use formulation patent expected to extend linzess® patent protection through  feb    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaqirwd announced today that the united states patent and trademark office uspto has issued a notice of allowance for a patent application covering methods of using linzess® linaclotide to treat patients with irritable bowe read more ironwood pharmaceuticals to present at leerink global healthcare conference feb    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the  leerink global healthcare conference on wednesday february   at  pm eastern time at the waldorf astoria hotel in new york a live webcast of read more ironwood pharmaceuticals provides fourth quarter  investor update jan    kb    fourth quarter linzess® linaclotide net product sales of  million as reported by forest laboratories inc up  quarter over quarter    million linzess net product sales in first full year of launch  million linzess net product sales since december  la read more ironwood pharmaceuticals announces alignment of workforce with priority growth platforms jan    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd announced today that it is reducing headcount by approximately  percent to align its workforce with its strategy to grow a leading gastrointestinal gi therapeutics company as detailed at ironwo read more ironwood pharmaceuticals to host fourth quarter  investor update call jan    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced it will host its fourth quarter  investor update conference call and webcast at  am eastern time on tuesday january   individuals interested in participating in the call should dial   read more ironwood pharmaceuticals to present at jp morgan healthcare conference jan    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the nd annual jp morgan healthcare conference on monday january   at  pm pacific time   pm eastern time at the westin st francis hotel in san francisco the prese read more ironwood pharmaceuticals details strategy to establish leading gastrointestinal therapeutics company dec    kb   — strong first year for linzess® linaclotide leading indicators reinforce significant opportunity ahead — — detailing seven gi clinical development programs with multiple opportunities to generate proof of concept data over next  months — cam read more ironwood pharmaceuticals to host investor day on december   nov    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will host a live webcast of its investor day which is being held on thursday december   beginning at  am et in new york city members of the ironwood leadership team will provide an indepth review of the com read more ironwood pharmaceuticals to present at credit suisse  healthcare conference nov    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the credit suisse  healthcare conference on tuesday november   at  pm mountain time pm eastern time a live webcast of ironwoods presentation will read more ironwood pharmaceuticals provides third quarter  investor update oct    kb   — third quarter linzess® linaclotide net product sales of  million as reported by forest laboratories inc — cambridge massbusiness wire ironwood pharmaceuticals inc nasdaqirwd today provided an update on its third quarter  and rec read more ironwood pharmaceuticals to host third quarter  investor update call oct    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced it will host its third quarter  investor update conference call and webcast at  am eastern time on tuesday october   individuals interested in participating in the call should dial   read more ironwood and astrazeneca initiate linaclotide phase iii trial in china for adults with ibsc sep    kb   cambridge mass  shanghaibusiness wire ironwood pharmaceuticals inc nasdaq irwd and astrazeneca pharmaceuticals co ltd today announced the initiation in china of a phase iii clinical trial of linaclotide for the treatment of adults with irritable bowel syndrome with constipation ibsc  read more ironwood pharmaceuticals to present at morgan stanley global healthcare conference sep    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd will present a corporate update at the morgan stanley global healthcare conference on tuesday september   at  pm eastern time at the grand hyatt new york a live webcast of ironwoods presentat read more ironwood pharmaceuticals appoints dr michael hall as senior vice president of clinical development aug    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced that michael hall mb bch has joined the company as senior vice president of clinical development dr hall will lead ironwoods clinical research clinical development clinical operations biostatistics read more ironwood pharmaceuticals provides second quarter  investor update jul    kb   second quarter linzess® linaclotide net product sales of  million as reported by forest laboratories inc cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today provided an update on its second quarter  and recent business activitie read more ironwood pharmaceuticals to host second quarter  investor update call jul    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced it will host its second quarter  investor update conference call and webcast at  am eastern time on tuesday july   individuals interested in participating in the call should dial   read more constella® linaclotide the first approved prescription therapy in a new class of treatments for adults with ibsc is now available in europe jun    kb   barcelona june th  – almirall sa almmc and ironwood pharmaceuticals inc nasdaq irwd announced the launch ofconstella®linaclotide mcg capsules once daily the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe ibsc read more ironwood pharmaceuticals announces partial exercise of underwriters option in public offering of common stock jun    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced that the underwriters of its previously announced public offering of shares of class a common stock have partially exercised their option to purchase an additional  shares at a public offering price o read more ironwood pharmaceuticals prices public offering of common stock may    kb   cambridge massbusiness wire ironwood pharmaceuticals inc nasdaq irwd today announced the pricing of an underwritten public offering of  shares of its class a common stock at a price of  per share to the public all of the shares are being offered by ironwood the gross procee read more showing  of  page              previous   next   add release to briefcase you are now leaving ironwoodpharmacom this link will take you to a website to which our privacy policy does not apply you are solely responsible for your interactions with that website ironwood pharmaceuticals  binney street cambridge ma  tel  fax  about us overview core values management team founders board of directors pharmaceutical advisory committee contact us transparency our medicines overview discovery of linaclotide global strategy rd overview approach collaborate overview accessing additional products globalization investors overview business principles events corp governance financial information stock information investor faqs press releases investor contacts news overview press releases social media multimedia resources join us overview career openings sales openings our community our expertise copyright   ironwood pharmaceuticals inc all rights reserved        privacy policy        terms of service       site design linzess® is a registered trademark of ironwood pharmaceuticals inc zurampic® duzallo™ are registered trademarks of astrazeneca ab corporation or its affiliates and are used herein under license